Inspiremd, INC. (NSPR) — SEC Filings

Overview

Inspiremd, INC. (NSPR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 19, 2025: InspireMD, Inc. announced on December 17, 2025, changes related to its board of directors and executive compensation. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its key executives. This 8-K filing al

Sentiment Summary

Across 49 filings, the sentiment breakdown is: 1 bearish, 48 neutral. The dominant filing sentiment for Inspiremd, INC. is neutral.

Filing Type Overview

Inspiremd, INC. (NSPR) has filed 28 8-K, 6 10-Q, 1 8-K/A, 1 DEFA14A, 2 DEF 14A, 2 10-K, 3 SC 13G, 6 SC 13G/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (49)

• InspireMD Announces Board and Executive Changes — 8-K · Dec 19, 2025 Risk: medium
  InspireMD, Inc. announced on December 17, 2025, changes related to its board of directors and executive compensation. The filing details the departure of certai
• InspireMD's Losses Widen Despite Revenue Growth, Liquidity Concerns Mount — 10-Q · Nov 10, 2025 Risk: high
  InspireMD, Inc. reported a significant increase in revenue for the three and nine months ended September 30, 2025, reaching $2.523 million and $5.830 million, r
• InspireMD, Inc. Files 8-K on Financials — 8-K · Nov 4, 2025 Risk: low
  InspireMD, Inc. filed an 8-K on November 4, 2025, reporting on its financial condition and operations. The filing also includes disclosures under Regulation FD
• InspireMD Files 8-K on Officer/Director Changes — 8-K · Sep 17, 2025 Risk: medium
  InspireMD, Inc. filed an 8-K on September 17, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain o
• InspireMD Files 8-K/A Amendment on Officer/Director Changes — 8-K/A · Sep 8, 2025 Risk: medium
  InspireMD, Inc. filed an amendment (8-K/A) on September 8, 2025, related to events on July 30, 2025. The filing concerns the departure of directors or certain o
• InspireMD Files 8-K on Financials and Disclosures — 8-K · Aug 5, 2025 Risk: low
  InspireMD, Inc. filed an 8-K on August 5, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statemen
• InspireMD Shows Stable Capital Structure in Q2 2025 Filing — 10-Q · Aug 4, 2025 Risk: medium
  InspireMD, Inc. filed its 10-Q for the period ending June 30, 2025, indicating a continued focus on its medical device operations. The company's financial state
• InspireMD Files 8-K: Agreements, Equity Sales, Officer Changes — 8-K · Jul 31, 2025 Risk: medium
  InspireMD, Inc. announced on July 30, 2025, several key events including entering into a material definitive agreement, unregistered sales of equity securities,
• InspireMD, Inc. Files 8-K with Financial Updates — 8-K · Jul 9, 2025 Risk: low
  InspireMD, Inc. filed an 8-K on July 9, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly Saguaro Resou
• InspireMD Files 8-K with Regulatory Updates — 8-K · Jun 24, 2025 Risk: low
  InspireMD, Inc. filed an 8-K on June 24, 2025, reporting events as of June 23, 2025. The filing includes information related to Regulation FD Disclosure, Other
• InspireMD Files 8-K with Regulatory Updates — 8-K · Jun 13, 2025 Risk: low
  InspireMD, Inc. filed an 8-K on June 13, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Events, a
• InspireMD Files 8-K on Shareholder Votes and Financials — 8-K · Jun 3, 2025 Risk: low
  InspireMD, Inc. filed an 8-K on June 3, 2025, reporting on the submission of matters to a vote of security holders and financial statements. The company, incorp
• InspireMD Files 8-K on Financials — 8-K · May 9, 2025 Risk: low
  InspireMD, Inc. filed an 8-K on May 9, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibi
• InspireMD, Inc. Files Q1 2025 10-Q Report — 10-Q · May 8, 2025 Risk: medium
  InspireMD, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly Saguaro Resources, Inc., is based in Miami, Florida, and
• InspireMD Files Proxy Materials — DEFA14A · Apr 16, 2025 Risk: low
  InspireMD, Inc. filed a Definitive Additional Materials (DEFA14A) on April 16, 2025. This filing is related to proxy materials and does not require a filing fee
• InspireMD Executive Compensation Details Revealed — DEF 14A · Apr 15, 2025 Risk: low
  InspireMD, Inc. filed its DEF 14A on April 15, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes informat
• InspireMD Files 2024 10-K, Details Financials — 10-K · Mar 12, 2025 Risk: medium
  InspireMD, Inc. filed its 10-K for the fiscal year ending December 31, 2024, on March 12, 2025. The company, formerly Saguaro Resources, Inc., is incorporated i
• InspireMD Announces CFO Departure, Appoints Interim CFO & New Directors — 8-K · Dec 12, 2024 Risk: medium
  InspireMD, Inc. announced on December 10, 2024, the departure of its Chief Financial Officer, Robert L. Buono, effective immediately. The company has appointed
• InspireMD Files 8-K — 8-K · Dec 9, 2024 Risk: low
  InspireMD, Inc. filed an 8-K on December 9, 2024, reporting on other events and financial statements. The company, formerly Saguaro Resources, Inc., is incorpor
• SC 13G Filing — SC 13G · Dec 4, 2024
• InspireMD Files 8-K on Officer/Director Changes — 8-K · Nov 25, 2024 Risk: medium
  InspireMD, Inc. filed an 8-K on November 25, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of certain of
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• InspireMD Files Q3 2024 10-Q Report — 10-Q · Nov 12, 2024 Risk: medium
  InspireMD, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter.
• SC 13G/A Filing — SC 13G/A · Oct 28, 2024
• InspireMD, Inc. Files 8-K for Material Definitive Agreement — 8-K · Oct 15, 2024 Risk: medium
  On October 9, 2024, InspireMD, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in
• InspireMD Files 8-K: Other Events & Reg FD Disclosure — 8-K · Oct 7, 2024 Risk: medium
  InspireMD, Inc. filed an 8-K on October 7, 2024, to report on other events and a Regulation FD disclosure. The filing does not contain specific financial figure
• InspireMD Files 8-K on Officer/Director Changes & Compensation — 8-K · Oct 1, 2024 Risk: medium
  InspireMD, Inc. filed an 8-K on October 1, 2024, reporting on events as of September 30, 2024. The filing primarily concerns the departure of directors or certa
• InspireMD Files 8-K with Financials and Disclosures — 8-K · Sep 16, 2024 Risk: low
  InspireMD, Inc. filed an 8-K on September 16, 2024, reporting on events including a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibit
• InspireMD Files 8-K on Financials — 8-K · Aug 6, 2024 Risk: low
  InspireMD, Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. Th
• InspireMD Files Q2 2024 10-Q — 10-Q · Aug 5, 2024 Risk: medium
  InspireMD, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operations. Key
• SC 13G/A Filing — SC 13G/A · Jul 11, 2024
• InspireMD, Inc. Files 8-K — 8-K · Jul 1, 2024 Risk: low
  InspireMD, Inc. filed an 8-K on July 1, 2024, reporting on other events and financial statements. The company, incorporated in Delaware, is based in Tel Aviv, I
• InspireMD Files 8-K, No New Material Info — 8-K · Jun 13, 2024 Risk: low
  InspireMD, Inc. (NSPR) filed an 8-K on June 13, 2024, to report under Regulation FD. The filing indicates that the company is not providing any new material inf
• InspireMD, Inc. Files 8-K on Shareholder Votes and Financials — 8-K · Jun 12, 2024 Risk: low
  InspireMD, Inc. filed an 8-K on June 12, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing indicates a cha
• InspireMD Files 8-K: Material Agreement and Other Events — 8-K · May 31, 2024 Risk: medium
  InspireMD, Inc. announced on May 31, 2024, that it entered into a Material Definitive Agreement. The company also reported on other events and filed financial s
• InspireMD Acquires Subsidiary for $1M — 8-K · May 28, 2024 Risk: low
  InspireMD, Inc. announced on May 28, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of its subsidiary, InspireMD Ltd.,
• SC 13G/A Filing — SC 13G/A · May 17, 2024
• InspireMD Files 8-K on Financials — 8-K · May 14, 2024 Risk: low
  InspireMD, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The
• InspireMD, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: low
  InspireMD, Inc. (NSPR) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. InspireMD, Inc. filed a 10-Q report for the period ending March 31, 2024. T
• SC 13G/A Filing — SC 13G/A · Apr 25, 2024
• InspireMD, Inc. Announces Annual Meeting of Stockholders — DEF 14A · Apr 18, 2024 Risk: low
  InspireMD, Inc. (NSPR) filed a Proxy Statement (DEF 14A) with the SEC on April 18, 2024. InspireMD, Inc. will hold its annual meeting of stockholders on June 10
• InspireMD Adds Two Directors to Board — 8-K · Apr 2, 2024 Risk: low
  InspireMD, Inc. announced on April 2, 2024, a change in its board of directors. The company elected two new directors, Mr. Eyal Leibovitz and Mr. Yishai Ben-Dor
• InspireMD Files 8-K for Reg FD and Financials — 8-K · Mar 26, 2024 Risk: low
  InspireMD, Inc. filed an 8-K on March 26, 2024, to report on Regulation FD disclosures and financial statements. The company, formerly Saguaro Resources, Inc.,
• InspireMD, Inc. Files 8-K on Financials — 8-K · Mar 6, 2024 Risk: low
  InspireMD, Inc. filed an 8-K on March 6, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The
• InspireMD, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 5, 2024 Risk: medium
  InspireMD, Inc. (NSPR) filed a Annual Report (10-K) with the SEC on March 5, 2024. InspireMD, Inc. filed its 2023 Form 10-K on March 5, 2024. The filing covers
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 14, 2024
• InspireMD Files 8-K, Confirms Nasdaq Listing & Corporate Details — 8-K · Jan 31, 2024
  InspireMD, Inc. filed an 8-K on January 31, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded company on The

Risk Profile

Risk Assessment: Of NSPR's 39 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Inspiremd, INC.'s most recent 10-Q filing (Nov 10, 2025):

• Revenue: $5.830M
• Net Income: $(37.025)M
• EPS: $(0.64)
• Debt-to-Equity: 0.22
• Cash Position: $63.403M
• Operating Margin: -644%
• Total Assets: $78.472M
• Total Debt: $14.358M

Key Executives

• Hamas
• Robert L. Buono
• Dr. Zvi Zilberman
• Dr. Shimon Y. Ekstein
• Mr. David M. J. M. Van den Broek
• Craig Shore
• Eyal Leibovitz
• Yishai Ben-Dor

Industry Context

InspireMD operates in the highly competitive medical device sector, specifically focusing on neurovascular and cardiovascular interventions. The industry is characterized by rapid technological advancements, stringent regulatory approvals (e.g., FDA), and significant R&D investment. Companies often rely on strategic partnerships and substantial capital raises to fund product development and market penetration.

Top Tags

financial-reporting (8) · financials (8) · filing (7) · disclosure (5) · corporate-governance (5) · 8-K (5) · 8-k (5) · Medical Devices (4) · regulatory-filing (4) · 10-Q (4)

Key Numbers

• Revenue for Q3 2025: $2.523M — Increased from $1.810M in Q3 2024
• Revenue for nine months ended Sep 30, 2025: $5.830M — Increased from $5.060M in the prior year period
• Net Loss for Q3 2025: $(12.708)M — Worsened from $(7.890)M in Q3 2024
• Net Loss for nine months ended Sep 30, 2025: $(37.025)M — Worsened from $(22.831)M in the prior year period
• Cash and cash equivalents as of Sep 30, 2025: $63.403M — Significantly increased from $18.916M at Dec 31, 2024
• Net cash provided by financing activities for nine months ended Sep 30, 2025: $55.569M — Increased from $16.889M in the prior year period
• Accumulated deficit as of Sep 30, 2025: $(290.531)M — Increased from $(253.506)M at Dec 31, 2024
• Net cash used in operating activities for nine months ended Sep 30, 2025: $(25.758)M — Increased from $(15.118)M in the prior year period
• Selling and marketing expenses for nine months ended Sep 30, 2025: $11.314M — Increased from $4.154M in the prior year period
• Common shares issued and outstanding as of Sep 30, 2025: 41,919,141 — Increased from 26,611,033 at Dec 31, 2024, indicating dilution
• Event Date: 20250730 — Earliest event reported in the filing
• Filing Date: 20250908 — Date the amendment was filed
• Central Index Key (CIK): 0001433607 — Unique identifier for InspireMD, Inc. with the SEC.
• Standard Industrial Classification (SIC): 3841 — Indicates the company operates in Surgical & Medical Instruments & Apparatus.
• Conformed Period of Report: 2025-06-30 — The end date of the financial period covered by this 10-Q filing.

Frequently Asked Questions